Transport
Bay County Health System, LLC
Bay County Health System, LLC was paid $6.50M by Medicaid between Jan 2018 and Nov 2024, across 187 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoBAY COUNTY HEALTH SYSTEM, LLC
PANAMA CITY, FL 32401
PANAMA CITY, FL 32401
33aNPI1720078041assigned 10/27/2005
33bProvider typeAmbulance
28Total paid$6.50M
24GClaims366,247
24DCodes billed187
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Ambulance providers in Florida
Rank by total paid#10 of 85
Median peer was paid$837K
This provider vs. median7.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official QUIRICONI, STEPHAN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 67,919 | $649K | |
| 2019 | 76,014 | $925K | |
| 2020 | 60,819 | $772K | |
| 2021 | 63,252 | $1.17M | |
| 2022 | 67,411 | $1.88M | |
| 2023 | 26,144 | $906K | |
| 2024incomplete | 4,688 | $195K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 18,807 | 15,905 | $1.14M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 14,824 | 12,316 | $879K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 7.4% | 3,947 | 1,099 | $480K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.8% | 11,230 | 9,027 | $440K |
| 36415 | Collection of venous blood by venipuncture | 5.7% | 18,439 | 13,535 | $369K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.3% | 2,928 | 2,476 | $345K |
| 41899 | Unlisted procedure, dentoalveolar structures | 5.1% | 587 | 525 | $328K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.0% | 3,796 | 2,980 | $259K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.5% | 2,729 | 2,083 | $162K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.3% | 3,542 | 1,026 | $148K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.9% | 1,845 | 1,606 | $126K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 2,693 | 2,226 | $108K |
175 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 1,104 | $101K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 603 | $80K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 2,847 | $79K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 2,080 | $71K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 766 | $60K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,413 | $54K |
| 80053 | Comprehensive metabolic panel | <1% | 20,449 | $53K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,124 | $50K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,407 | $43K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,252 | $42K |
| 01999 | <1% | 1,498 | $37K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 291 | $37K |
| 82962 | <1% | 3,758 | $36K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,993 | $33K |
| A9270 | Non-covered item or service | <1% | 5,640 | $32K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,580 | $32K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 28,133 | $32K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,317 | $31K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,052 | $30K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 898 | $28K |
| 97161 | <1% | 181 | $25K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 807 | $24K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,495 | $24K |
| 92523 | <1% | 169 | $24K | |
| 81003 | <1% | 5,763 | $23K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,977 | $21K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,770 | $21K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,788 | $19K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,827 | $19K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,424 | $19K |
| 81001 | <1% | 8,582 | $18K | |
| 80047 | <1% | 4,436 | $17K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 207 | $17K |
| G0378 | Hospital observation service, per hour | <1% | 1,205 | $17K |
| 84484 | <1% | 9,203 | $17K | |
| 84703 | <1% | 4,537 | $16K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,997 | $15K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,293 | $15K |
| 87400 | <1% | 735 | $14K | |
| 73610 | <1% | 541 | $14K | |
| 87503 | <1% | 457 | $13K | |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | <1% | 317 | $13K |
| C1769 | Guide wire | <1% | 454 | $13K |
| 73630 | <1% | 628 | $11K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,772 | $11K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,712 | $11K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,928 | $10K |
| 83735 | <1% | 5,465 | $9K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,879 | $9K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,243 | $9K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 588 | $9K |
| 73564 | <1% | 266 | $8K | |
| 85610 | <1% | 4,296 | $8K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,292 | $8K |
| 73110 | <1% | 190 | $8K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,729 | $8K |
| 90714 | <1% | 319 | $8K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 239 | $7K |
| 73030 | <1% | 382 | $7K | |
| 84439 | <1% | 1,721 | $7K | |
| 72131 | <1% | 97 | $7K | |
| 82550 | <1% | 2,191 | $7K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,190 | $6K |
| 84702 | <1% | 2,162 | $6K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 793 | $5K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,707 | $5K |
| 73562 | <1% | 255 | $5K | |
| 73130 | <1% | 320 | $5K | |
| 87040 | <1% | 1,429 | $5K | |
| 83690 | <1% | 4,638 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,256 | $5K |
| 80061 | Lipid panel | <1% | 3,074 | $5K |
| 80076 | <1% | 2,699 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,595 | $5K |
| 85730 | <1% | 3,383 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 932 | $4K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 230 | $4K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 91 | $4K |
| 87430 | <1% | 168 | $4K | |
| 87077 | <1% | 1,486 | $4K | |
| 81015 | <1% | 698 | $4K | |
| 83605 | <1% | 2,216 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,048 | $3K |
| 83880 | <1% | 2,205 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 86 | $3K |
| 87070 | <1% | 185 | $3K | |
| 86901 | <1% | 981 | $3K | |
| 85027 | <1% | 760 | $3K | |
| 85018 | <1% | 280 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 31 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,895 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 757 | $3K |
| 41874 | <1% | 28 | $2K | |
| 80320 | <1% | 1,463 | $2K | |
| 96376 | <1% | 899 | $2K | |
| 87186 | <1% | 1,077 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,378 | $2K |
| J3490 | Unclassified drugs | <1% | 808 | $2K |
| 82607 | <1% | 933 | $2K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 475 | $2K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 271 | $2K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 123 | $2K |
| 82553 | <1% | 521 | $1K | |
| 99234 | <1% | 434 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 573 | $1K |
| 82803 | <1% | 275 | $1K | |
| 36600 | <1% | 252 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,462 | $1K |
| 93970 | <1% | 78 | $1K | |
| 82375 | <1% | 265 | $1K | |
| 83050 | <1% | 265 | $1K | |
| 72100 | <1% | 100 | $1K | |
| 80329 | <1% | 323 | $1K | |
| 3044F | <1% | 146 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 150 | $1K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 57 | $1K |
| 85379 | <1% | 624 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 304 | $1K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 210 | $1K |
| 86900 | <1% | 756 | $924.68 | |
| 73502 | <1% | 155 | $905.49 | |
| 74018 | <1% | 103 | $902.69 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 332 | $872.84 |
| 76801 | <1% | 80 | $830.34 | |
| 86850 | <1% | 378 | $701.40 | |
| 86140 | <1% | 466 | $661.09 | |
| 80305 | <1% | 256 | $650.42 | |
| 82140 | <1% | 152 | $614.80 | |
| 87807 | <1% | 26 | $478.05 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 75 | $414.38 |
| 82728 | <1% | 269 | $375.34 | |
| 73090 | <1% | 13 | $335.20 | |
| 73080 | <1% | 13 | $323.38 | |
| 84481 | <1% | 227 | $299.84 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 127 | $256.46 |
| 85652 | <1% | 616 | $239.47 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 220 | $229.30 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 73 | $223.64 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 904 | $223.51 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 323 | $181.08 |
| 82248 | <1% | 119 | $162.97 | |
| 93971 | <1% | 29 | $142.10 | |
| 82746 | <1% | 79 | $110.74 | |
| 84550 | <1% | 48 | $82.24 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 55 | $80.00 |
| 82570 | <1% | 281 | $79.86 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 16 | $78.84 |
| 82805 | <1% | 56 | $76.33 | |
| 72110 | <1% | 29 | $70.07 | |
| 83540 | <1% | 141 | $58.54 | |
| 87081 | <1% | 15 | $47.24 | |
| 82043 | <1% | 194 | $38.49 | |
| 80074 | <1% | 15 | $33.78 | |
| 83550 | <1% | 70 | $29.48 | |
| 82150 | <1% | 161 | $28.16 | |
| J1815 | Injection, insulin, per 5 units | <1% | 27 | $24.51 |
| 84100 | <1% | 60 | $23.29 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 19 | $22.22 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 17 | $20.57 |
| 80069 | <1% | 77 | $10.19 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 467 | $0.00 |
| 99152 | 0% | 182 | $0.00 | |
| 81025 | 0% | 36 | $0.00 | |
| 83970 | 0% | 16 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 46 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 17 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 45 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 253 | $0.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 127 | $0.00 |
| 93000 | 0% | 17 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 181 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 14 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 22 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 15 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialQUIRICONI, STEPHAN (CFO)
Parent organizationBAY COUNTY HEALTH SYSTEM, LLC
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.